Prostanoids are a series of bioactive lipid metabolites that function in an autacoid manner via activation of cognate G-protein-coupled receptors (GPCRs). Here, we report the crystal structure of human prostaglandin (PG) E receptor subtype EP3 bound to endogenous ligand PGE 2 at 2.90 Å resolution. The structure reveals important insights into the activation mechanism of prostanoid receptors and provides a molecular basis for the binding modes of endogenous ligands.
), which provided molecular insights into the inactive state of the receptor. To date, however, the molecular mechanisms underlying recognition of endogenous lipid ligands (for example, PGE 2 ) and receptor activation have remained obscure.
To obtain the structure of active EP3, we screened thermostabilized receptors in the presence of PGE 2 (Supplementary Figs. 1 and 2) and designed a mutant receptor containing four amino acid substitutions that had no effect on pharmacology or ligand binding ( Supplementary Fig. 3 ). To promote crystallization, we removed 42 and 31 residues (M1-G42 and I360-R390) from the N and C termini of the receptor, respectively. Furthermore, an improved variant of the thermostabilized apocytochrome b 562 RIL (mbIIG2) was fused to the third intracellular loop (IL3). The modified EP3 was crystallized in lipidic cubic phase, and the crystal structure was solved at 2.9 Å resolution (Supplementary Table 1 ). Two copies of EP3 bound to PGE 2 were present in the asymmetric unit ( Supplementary Fig. 4 ). Because both structures are nearly identical (r.m.s. deviation Cα ~ 0.1 Å for the receptor), hereafter we focus on the description of chain A.
EP3 folds into a canonical seven-transmembrane (TM) helical bundle. Extracellular loop (EL) 2 forms a β -hairpin loop, which is stabilized by the highly conserved disulfide bond between C130 3.25 (superscripts denote Ballesteros-Weinstein numbering 3 ) and C208 EL2 (Fig. 1a) . The β -hairpin loop in EL2, which resembles those of EP4 and rhodopsin ( Supplementary Fig. 5a ), tightly caps the extracellular region. In contrast to EP4, TM1 and TM7 of EP3 tightly seal the ligand-entry site, thereby completely occluding bound PGE 2 from the exterior ( Fig. 1b; Supplementary Fig. 5b,c) . Elongated electron densities are present in proximity to the ligandbinding site, to which phospholipids (palmitoyloleoylphosphatidylcholine, POPC) were tentatively assigned ( Supplementary Fig. 6 ). These phospholipids are located between the two EP3 protomers, apparently stabilizing the dimer interaction. Furthermore, because both PGE 2 and phospholipids possess polar head groups and hydrophobic alkyl chains, these phospholipids might mimic the initial binding step of PGE 2 . Additionally, because the noncrystallographic interdimeric contact region includes the putative ligand-entry site, dimer formation of the receptor may affect binding and/or dissociation of the ligand.
In contrast to most solved GPCR structures, helix 8 of EP3 is oriented almost vertically with respect to the membrane ( Supplementary Fig. 7 ). EP3 exists in several isoforms resulting from splicing variants of the C-terminal tail at position Q359, which is located at the tip of helix 8. Constitutive activities vary among the C-terminal variants, and truncation of the tail at Q359 increases the constitutive activity 4 . Our crystallization construct is truncated at Q359, potentially affecting the conformation of helix 8 ( Supplementary Fig. 1 ). Recent work showed that the noncanonical conformation of helix 8 stabilizes the active-like conformation in angiotensin II receptor AT 2 (ref. 5 ). Therefore, the noncanonical conformation of helix 8 of EP3 might also be related to its active-like conformation. The effect of C-terminal sequences on the conformation of helix 8 should be verified in future studies.
The endogenous agonist PGE 2 adopts an L-shape conformation in the orthosteric-binding pocket formed by residues in TMs 1-3, 6, and 7, and EL2 ( Fig. 2; Supplementary Fig. 8 Table 2 ) and R 7.40 mutations of EP2, EP4, FP, IP, and TP decrease ligand binding [6] [7] [8] [9] . The alkyl chain of the PGE 2 , called the ω -chain, extends into the side pocket formed by TMs 3, 5-7, and EL2, where it forms hydrophobic interactions with M137 3.32 , F209
EL2
, and V332 7.39 (Fig. 2) . The hydroxyl groups at C11 and C15 interact with M58 respectively (Fig. 2) . Consistent with this, mutation of M58 1.42 A or removal of the 11-hydoxyl group from PGE 2 (11-deoxy PGE 2 ) slightly attenuated signaling responses ( Fig. 2; Supplementary Figs . 9, 10, and 11a,b). Furthermore, 15-keto-PGE 2 (natural metabolite of PGE 2 ) greatly diminished signaling activity ( Supplementary  Fig. 11b,c) , highlighting the importance of the interaction between D99 2.50 and the 15-hydroxyl group of PGE 2 .
Compared to the inactive state of the EP4 receptor, our structure exhibits a notable conformational change in TMs 1 and 5. Specifically, the extracellular parts of TM1 and TM5 are displaced inward by 3.5 Å and 2.9 Å, respectively (Fig. 3a) . In addition, EL2 slightly shifts toward the ligand and more tightly packs extracellular region ( Supplementary Fig. 12 ). On the other hand, conformational changes are also observed in the cytoplasmic part of the receptor. TMs 5 and 6 are displaced outward by 2.8 Å and 7.5 Å, respectively, and TM7 is rearranged inward by 5.3 Å (Fig. 3b) , indicating that EP3-PGE 2 is in an active-like state.
The EP3 receptor couples with the G i/o protein. Among G i/ocoupled GPCRs, the first crystal structure to be reported was that of opsin, the ligand-free form of rhodopsin, bound to a C-terminal peptide of the Gα subunit of transducin (Gα CT) 10 . Recently, cryoelectron microscopy (cryo-EM) structures of µ -opioid receptor (µ OR) 11 , adenosine A 1 receptor 12 , and serotonin 5-HT 1B receptor 13 in complex with G i/o protein were reported. In these structures, TM6 is displaced further than that in the PGE 2 -bound EP3 structure presented here. The position of TM6 of EP3 is closer to that of opsin-Gα CT and µ OR-G i1 than those of A 1 -G i2 and 5-HT 1B -G o ( Supplementary Fig. 13 ).
Like the active states of other class A GPCRs, the EP3 receptor exhibits rearrangements of the highly conserved D/ERY motif on the intracellular side of TM3 and the NPxxY motif in TM7 ( Fig. 3c ; Supplementary Fig. 14) . In EP3, R155
3.50 of the D/ERY motif adopts an extended conformation. In some GPCRs, the sodium-binding pocket is located between TMs 2, 3, and 7 and accommodates a single sodium ion that acts as a negative allosteric modulator 14 . In PGE 2 -bound EP3, the pocket-forming residues (D99 2.50 , S144 3.39 , N338 7.45 , and D342 7.49 ) are so closely arranged that there is no space for sodium binding, hinting at an active-like structure ( Fig. 3c ; Supplementary Fig. 14) . Along with the interaction between D99 2.50 and the 15-hydroxyl group of PGE 2 , whose importance is addressed above, elimination of the allosteric sodium ion by PGE 2 may be one of the mechanisms underlying receptor activation.
The PGE 2 ω -chain extends toward L298 6.51 and the conserved W295 6 .48 residue of the CWxP motif at the end of hydrophobic . Consistent with this, mutations of F234 5.43 A, W295 6.48 F, or L298 6.51 A exhibited reduced signaling activity (Supplementary Figs. 9 and 10). To date, several lipid-binding GPCR structures have been reported in an antagonist-bound inactive state and/or an agonist-bound active-like state. The structures of sphingosine-1-phosphate receptor S1P 1 (ref. 15 ) and lysophosphatidic acid receptor LPA 1 (ref. 16 ) were solved in inactive states, and that of cannabinoid receptor CB 1 (refs 17, 18 ) was solved in both inactive and active-like states. Although rhodopsin is also a lipidbinding GPCR, the active state (meta II) was solved in complex with (Gα CT) 19 . In these structures, alkyl chains or hydrophobic moieties of ligands extend toward TMs 5 and 6 ( Supplementary Fig. 15 ). In rhodopsin and CB 1 , the rearrangement of the conserved W 6.48 was suggested to be involved in receptor activation 18, 19 . The position of W 6.48 in EP3 overlaps with the corresponding position in meta II and agonist-bound CB 1 , but not that in antagonist-bound S1P 1 and LPA 1 ( Supplementary Fig. 15 ). These observations suggest that the interaction between ω -chain of PGE 2 and residues around W295 6.48 of EP3 is important for the receptor activation.
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Methods
General methods.
No statistical methods were used to predetermine sample size. The experiments were not randomized, and the investigators were not blinded to allocation during experiments or outcome assessment.
Protein engineering for structural studies. To facilitate expression, purification, and crystallography, a human EP3 construct was generated with several modifications: The N-and C-termini were truncated before S43 and Q359, respectively. HRV 3 C protease recognition sites were introduced along with linker sequence (TS at the N-terminus and LE at the C-terminus). Two N-linked glycosylation sites in EL2 and EL3 were removed by mutation (N217Q and N308Q). To enhance thermostability, four mutations (A173 4.41 I, V185 4.53 S, S258 5.65 D, and C289 6.42 L) were introduced. These point mutations were identified by the Saccharomyces cerevisiae expression method 20 , and the thermostabilities of the mutants were validated by fluorescence detection size-exclusion chromatography-based thermostability assay (FSEC-TS) 21 ( Supplementary  Fig. 2a ). To facilitate crystallogenesis, an improved variant of apocytochrome b 562 RIL (mbIIG2), in which the R98I and L106G mutations 22 were introduced and residues from 41 to 62 were replaced with a GSGSG linker (Kimura, K. T., Asada, H., Inoue, A., Kadji, F. M. N., Im, D., Mori, C., Arakawa, T., Hirata, K., Nomura, Y., Nomura, N., Aoki, J., Iwata, S., and Shimamura, T., manuscript in revision), was inserted into the third intracellular loop between residues A264 and A271. To facilitate purification, an N-terminal FLAG epitope was inserted after the signal peptide and a C-terminal octa-histidine tag was introduced after EGFP. The final crystallization construct, EP3-mbIIG2, is shown in Supplementary Fig. 1 .
FSEC-TS.
FSEC-TS was performed as previously described 20, 21 with minor modifications. Briefly, vacuolar protease-deficient S. cerevisiae FGY217 (MATα , ura3-52, lys2Δ 201, and pep4Δ ) was transformed with DNA fragments encoding EP3 mutants and SmaI-digested pDDGFP-2. Transformants were selected on Ura − plates at 30 °C. Transformant colonies were grown in Ura − media, and expression of EP3 was induced with 2% (w/v) galactose. After shaking for 22 h at 30 °C, the cells were harvested and disrupted in suspension buffer (50 mM HEPES-NaOH (pH 7.5), 5 mM EDTA, 10% (v/v) glycerol, 0.12 M sorbitol, and protease inhibitor cocktail (Nacalai Tesque)) with zirconia/silica beads (BioSpec). Unbroken cells and debris were pelleted by centrifugation, and the supernatant was ultracentrifuged at 100,000g. The pelleted membranes were solubilized in suspension buffer supplemented with 1% (w/v) n-dodecyl-β -d-maltopyranoside (DDM; Anatrace) and 0.2% (w/v) cholesteryl hemisuccinate (CHS) for 1 h. Insoluble material was pelleted by ultracentrifugation at 100,000g, and supernatants were heated for 30 min at the indicated temperatures. FSEC was performed using an ENrich SEC 650 10 × 300 column (Bio-Rad) on a LaChrom Elite HPLC system (Hitachi). The column was pre-equilibrated with running buffer (20 mM HEPES-NaOH (pH 7.5), 150 mM NaCl, 0.03% (w/v) DDM), and fluorescence emission at 525 nm was measured after excitation at 483 nm.
Protein expression and purification. The Bac-to-Bac Baculovirus Expression System (Invitrogen) was used to generate high-titer ( > 10 8 viral particles per ml) recombinant baculovirus. Spodoptera frugiperda (Sf9) cells (Invitrogen) at a density of 3-4 × 10 6 cells per ml were infected by viral stock at an MOI (multiplicity of infection) of 1. In addition to the virus, PGE 2 was added to the cell culture at a final concentration of 1 μ M. Transfected cells were cultured at 27 °C for 70 h, then collected by centrifugation and stored at − 80 °C until use.
Frozen insect cells expressing EP3 were disrupted by thawing and repeated dounce homogenization in a hypotonic buffer containing 10 mM HEPES-NaOH (pH 7.5), 10 mM MgCl 2 , 20 mM KCl, 1 µ M PGE 2 , and protease inhibitor cocktail. After ultracentrifugation at 100,000g for 30 min, cell pellets were resuspended in high-osmolarity buffer (10 mM HEPES-NaOH (pH 7.5), 1.0 M NaCl, 10 mM MgCl 2 , 20 mM KCl, 1 µ M PGE 2 , and protease inhibitor cocktail), and then homogenized extensively. Soluble and membrane-associated proteins were removed from the suspension by centrifugation. This procedure was repeated twice. Purified membranes were resuspended in suspension buffer containing 30 mM HEPES-NaOH (pH 7.5), 750 mM NaCl, 5 mM imidazole, 1 mg ml
iodoacetamide, 10 µ M PGE 2 , and protease inhibitor cocktail, and incubated at 4 °C for 30 min. DDM, CHS, and sodium cholate were added at final concentrations of 1% (w/v), 0.2% (w/v), and 0.2% (w/v), respectively, and incubation was continued for an additional 2 h. The supernatant was isolated by ultracentrifugation at 100,000 g for 30 min, and then incubated with Ni-NTA Superflow resin (Qiagen) at 4 °C overnight. The resin was washed with ten column volumes of 30 mM HEPES-NaOH (pH 7.5), 750 mM NaCl, 0.1% (w/v) DDM, 0.03% (w/v) CHS, 0.02% (w/v) sodium cholate, 5 mM imidazole, and 10 µ M PGE 2 . The protein was eluted with five column volumes of 30 mM HEPES-NaOH (pH 7.5), 750 mM NaCl, 0.1% (w/v) DDM, 0.03% (w/v) CHS 0.02% (w/v), sodium cholate, 500 mM imidazole, and 10 µ M PGE 2 . Next, the nickel-resin eluate supplemented with CaCl 2 at a final concentration of 2 mM was loaded onto anti-FLAG M1 resin and washed with three column volumes of 30 mM HEPES-NaOH (pH 7.5), 750 mM NaCl, 0.1% (w/v) DDM, 0.03% (w/v) CHS, 0.02% (w/v) sodium cholate, 2 mM CaCl 2 , and 10 µ M PGE 2 . DDM was then gradually exchanged over 1 h into a buffer with 0.01% (w/v) lauryl maltose neopentyl glycol (MNG), and the NaCl concentration was lowered to 100 mM. The protein was eluted from the anti-FLAG M1 affinity resin with 0.2 mg ml −1 FLAG peptide and 5 mM EDTA in the presence of 10 µ M PGE 2 . The N-terminal FLAG tag and C-terminal GFP and His tags were then removed by overnight digestion with His-tagged HRV 3 C protease at 1:30 w/w (3 C:EP3-mbIIG2) in the presence of 100 µ M PGE 2 . Ni-Sepharose resin (GE Healthcare) reverse binding was performed to remove cleaved GFP and the 3 C protease. The monomeric fraction was purified by size-exclusion chromatography on a Superdex 200 Increase 10/300 GL gel filtration column (GE Healthcare) in 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, 0.01% (w/v) MNG, 0.001% (w/v) CHS, and 10 μ M ONO-AE3-240, and ONO-AE3-240 was added to the collected fractions at a final concentration of 500 µ M. The purified EP3-mbIIG2 was concentrated to 40-50 mg ml −1 using a 50 kDa molecular mass cut-off Amicon Ultra concentrator (Millipore).
Lipidic cubic phase crystallization. Protein samples of EP3 in complex with PGE 2 were mixed with molten lipid (monoolein and cholesterol 10:1 by mass) at a weight ratio of 1:1.5 (protein:lipid) using two syringes to create a lipidic cubic phase (LCP) 23 . The mixture was dispensed onto glass sandwich plates (Molecular Dimensions) in 30-nl drops and overlaid with 600 nl precipitant solution using a Gryphon robot (Art Robbins Instruments). Plates were placed in an incubator Data collection and structure determination. X-ray diffraction data were collected at the BL32XU of SPring-8 on a Dectris EIGER X 9 M detector (X-ray wavelength 1.0000 Å). The diffraction dataset was collected automatically using the ZOO system developed at SPring-8. Small wedge datasets (10° each) were collected using a beam size of ~10 μ m × 15 μ m from automatically recognized crystal positions based on raster scan results using SHIKA 24 . Exposure conditions were automatically adjusted using KUMA 25 such that each crystal absorbed a dose of ~ 10 MGy. All collected datasets were processed automatically using KAMO 26 . The datasets were indexed and integrated using XDS 27 . Datasets indexed with consistent unit cell parameters were subjected to hierarchical cluster analysis based on unitcell similarity using BLEND 28 and then merged. The cluster of all datasets resulted in the best merging result, consisting of 683 datasets with highest overall CC 1/2 (Pearson correlation coefficient calculated between two random half data sets). The structure of EP3-mbIIG2 was solved by molecular replacement with Phaser 29 using the receptor portion of EP4 (PDB code 5YWY) and the structure of bRIL in A 2A -bRIL (PDB code 4EIY) as search models. The resultant solution was improved by manual iterative building in COOT 30 , followed by refinement with REFMAC5 31 and PHENIX 32 . In the regions of the model for which side chain density was too weak to unambiguously assign a conformation, we cut the side chains (C47, Y165, A166, S167, K170, and R172 of chain A and B, and E324 of chain A, Y77, S126, R160, V193, R259, A264, and W273 of chain B; all residues locate around the loop regions). Because mbIIG2 was almost disordered, we modeled only the connective region with EP3 (A1, D2, K104 of chain A, and main chain atoms of L3, Y105, G106 of chain A, and A1, K104, Y105, G106 in chain B). In this model, 99.8% of residues were in favored regions of the Ramachandran plot, and all others were in allowed regions. The statistics for data collection and refinement are shown in Supplementary Table 1. Figures were prepared using PyMOL (Schrödinger).
Radioligand-binding assay. FLAG-tagged wild-type and mutants of human EP3 cDNA were subcloned into the mammalian expression vector pcDNA3.1 (Thermo Fisher Scientific), and the resultant plasmid was transfected into HEK293 cells using Lipofectamine 2000 (Thermo Fisher Scientific). After culture for 24 h, the cells were harvested and homogenized in 25 mM Tris-HCl (pH 7.5) containing 0.25 M sucrose, 10 mM MgCl 2 , 1 mM EDTA, and 0.1 mM phenylmethylsulfonyl fluoride. The homogenate was ultracentrifuged at 100,000g for 30 min, and the pellet was suspended in binding buffer (20 mM MES-NaOH (pH 6.0), 10 mM MgCl 2 and 1 mM EDTA) and used as crude membranes in binding assays. Protein concentrations were determined using the BCA assay (Thermo Fisher Scientific).
[ 3 H]PGE 2 (PerkinElmer) affinity (K d ) was determined by saturation binding assay, which was performed by incubating varying concentrations of [ 3 H]PGE 2 with 5-50 µ g of crude membranes at 30 °C for 1 h in a final volume of 100 µ l binding buffer. Non-specific binding was determined using a 100-fold excess of non-radiolabeled PGE 2 . The amount of protein used was chosen such that the total binding was 2-10-fold higher than non-specific binding. After the reaction, the mixture was rapidly filtered through Whatman GF/B glass filters presoaked in 0.3% (v/v) polyethylenimine. The filter was then washed twice with 5 ml of ice-cold K-P buffer (1.32 mM K 2 HPO 4 , 8.68 mM KH 2 PO 4 , 10 mM MgCl 2 , 1 mM EDTA). The radioactivity associated with the filter was measured in 2.5 ml of ClearSol I scintillation liquid (Nacalai Tesque) using an AccuFLEX LCS-8000 liquid scintillation counter (Hitachi). Specific binding was calculated by subtracting nonspecific binding from total binding. All binding assay measurements were analyzed using Prism (GraphPad).
TGFα shedding assay. Transforming growth factor α (TGFα ) shedding assay was performed as previously described 33 . Briefly, HEK293 cells were transfected with three plasmids encoding FLAG-tagged EP3 receptors, alkaline phosphatase (AP)-tagged TGFα , and Gα q/i1 chimeric G protein. After The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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